Perioperative management of drugs commonly used in patients with rheumatic diseases: a review

André Silva Franco, Leandro Ryuchi Iuamoto, Rosa Maria Rodrigues Pereira*

Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, BR.

Rheumatic diseases are very prevalent, affecting about 7 million people in North America; they affect the musculoskeletal system, often with systemic involvement and potential for serious consequences and limitation on quality of life. Clinical treatment is usually long-term and includes drugs that are considered either simple or complex and are occasionally unknown to many health professionals who do not know how to manage these patients in emergency units and surgical wards. Thus, it is important for clinicians, surgeons and anesthesiologists who are involved with rheumatic patients undergoing surgery to know the basic principles of therapy and perioperative management. This study aims to do a review of the perioperative management of the most commonly used drugs in rheumatologic patients. Manuscripts used in this review were identified by surveying MEDLINE, LILACS, EMBASE, and COCHRANE databases and included studies containing i) the perioperative management of commonly used drugs in patients with rheumatic diseases; and ii) rheumatic diseases. They are didactically discussed according to the mechanism of action and pharmacokinetics; and perioperative management. In total, 259 articles related to the topic were identified. Every medical professional should be aware of the types of drugs that are appropriate for continuous use and should know the various effects of these drugs before indicating surgery or assisting a rheumatic patient postoperatively. This information could prevent possible complications that could affect a wide range of patients.

KEYWORDS: Rheumatic Diseases; Drugs; Perioperative Period; Inflammation Mediators.

Franco AS, Iuamoto LR, Pereira RM. Perioperative management of drugs commonly used in patients with rheumatic diseases: a review. Clinics. 2017;72(6):386-390

Received for publication on October 18, 2016; First review completed on December 27, 2016; Accepted for publication on February 24, 2017

*Corresponding author. E-mail: rosamariarp@yahoo.com

INTRODUCTION

Rheumatic diseases are very prevalent, affecting about 7 million people in North America (1); they affect the musculoskeletal system, often with systemic involvement and potential for serious consequences and limitation on quality of life (2,3). The diagnoses of such diseases are not simple and may require additional tests and multidisciplinary approaches (4). Clinical treatment is usually long-term, using drugs that are considered either simple or complex and are occasionally unknown to many health professionals. Such a lack of understanding could lead to difficulty in managing these patients in primary care services, emergency units and surgical wards (4).

An estimated 33 million patients undergo surgical procedures each year in the United States. Serious adverse events occur in more than 1 million of these patients at an annual estimated cost of US$ 25 billion. With an aging population, it is expected that surgical indications and surgical costs will increase by 25% and 50%, respectively, and that the cost of perioperative complications will double (5).

The incidence of postoperative infections ranges from 0.5 to 6.0%, depending on the medical center, the type of surgery, and the surgical site (6). Rheumatic patients, however, are at increased risk of developing postoperative infections. Approximately 25% of all patients with rheumatoid arthritis will require surgery within the first 20 years of disease, excluding emergency procedures not related to preexisting maladies. The major complication of elective orthopedic procedures is surgical site infection, with an incidence between 2-15% and the drugs used by these patients cannot be ruled out as a contributing factors to such high rates (7-11).

Considering the epidemiology of such diseases and professional accountability for the use of prescribed drugs, it is imperative that clinicians, surgeons and anesthesiologists who are involved with rheumatic patients undergoing surgery know the basic principles of drug therapy and perioperative management (12-14).

The purpose of the present study is to evaluate the drugs that are most commonly used in patients with rheumatic diseases and to guide the perioperative management of these drugs.

METHODS

Manuscripts used in this review were identified by surveying MEDLINE, LILACS, EMBASE, and COCHRANE.
results

The search of MEDLINE, EMBASE, LILACS and COCHRANE databases provided 237 studies. After removing the duplicates, 223 remained. Of these, 18 studies were not full text; and 172 were discarded because after reviewing the abstracts these papers clearly did not meet the eligibility criteria. Twelve additional studies that met the criteria for inclusion were identified by checking the references of other relevant papers that did not meet our criteria. The full texts of the remaining 45 citations were examined in more detail. No unpublished relevant studies were obtained. 6 articles were not used in this review based on our exclusion criteria.

It is also important to note the lack of randomized, double-blind researches/trials comparing the safety of drugs in rheumatic diseases in emergency procedures and not only in elective surgeries.

In our review, we only found articles about rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis, excluding any other rheumatic diseases. Regarding the treatment and perioperative management of such conditions, we found information on Nonsteroidal antiinflammatory drugs and aspirin (NSAIDs), glucocorticoids, Disease-modifying antirheumatic drugs (DMARDs) and biological drugs, presented as follows.

### Table 1 - Nonsteroidal anti-inflammatory drugs.

| NSAID                  | Half-life (hours) | Withdrawal before surgery |
|-----------------------|-------------------|---------------------------|
| Naproxen              | 1-2               | 3 days                    |
| Ibuprofen             | 1.6-1.9           | 10 hours                  |
| Diclofenac            | 2                 | 10 hours                  |
| Indomethacin          | 4.5               | 1 day                     |
| COX-2 inhibitor (Celecoxib) | 11              | maintain usual dosage    |

Pituitary-adrenal axis suppression

Pituitary-adrenal axis suppression occurs in patients who are on chronic use of glucocorticoids. If the doses are above the physiologic range (10-12 mg of cortisol/day), 30 days is probably the minimal for inhibition of endogenous glucocorticoid synthesis. There is evidence that the use of 20 mg of prednisone for 5 days is already sufficient to inhibit cortisol synthesis (28). In such cases, it is necessary to supplement the glucocorticoid dose in the perioperative period due to surgical stress, even with the increased risk of infection and hindering of wound healing induced by these drugs (29,30) (Table 2).

A decade ago, high doses of corticosteroids were given to patients with adrenal insufficiency before surgery. More recent studies prefer to assess therapy length, corticosteroid...
dose and degree of surgical stress to prescribe the minimum amount of drug (31) (Table 2). An ACTH stimulation test could be performed during preoperative evaluation to verify the need for corticosteroid supplementation (32), although the low sensitivity observed in patients with secondary adrenal insufficiency frequently requires additional testing (33).

**Disease-modifying antirheumatic drugs**

Disease-modifying antirheumatic drugs (DMARDs) are a heterogeneous group of drugs and their main benefit is to delay the progression of some rheumatologic diseases by changing its natural history. Most prospective and retrospective studies have suggested that methotrexate and other DMARDs may be continued during the perioperative period without compromising healing or increasing the risk of infection (12,34).

Hydroxychloroquine in lupus patients, reduces disease activity, cardiovascular risk, insulin resistance, thromboembolic events, infection risk and mortality (35–38), and this drug should not be discontinued during the perioperative period.

Table 3 summarizes the half-life, mechanism of action, side effects and management regarding the perioperative period.

### Table 2 - Glucocorticoid prescription according to surgical aggression.

| Type of surgery / surgical stress | Surgical Procedures | Glucocorticoid prescription |
|-----------------------------------|---------------------|-----------------------------|
| Superficial procedure (anesthesia < 1 hour) | Ophthalmologic surgeries, herniorrhaphy | Not necessary. |
| Small surgical stress | Carpal tunnel release, colonoscopy, knee arthroscopy | Maintain daily dosage. |
| Mild surgical stress | hip arthroplasty, knee arthroplasty, laparoscopic abdominal surgery, pulmonary biopsy | 25 mg hydrocortisone IV or 5 mg methylprednisolone IV on the procedure day |
| Important surgical stress | bilateral hip arthroplasty, total ankle arthroplasty, spine surgery, open abdominal surgery, hysterectomy | 50-75 mg hydrocortisone IV or 10-15 mg methylprednisolone IV on the procedure day; return to previous dosage by lowering it on the next 1 to 2 days |

Adapted from references 14 and 34.

### Table 3 - DMARDs - mechanism of action, half-life and management in the perioperative period.

| Drug | Half-life | Mechanism of action | Management |
|------|-----------|---------------------|------------|
| Methotrexate | 3-10 hours | Dihydrofolate reductase inhibition | Maintain usual dosage* |
| Hydroxychloroquine | 32-50 hours | Lysosomal membrane stabilization and reduces IL-1 and TNF synthesis | Maintain usual dosage |
| Leflunomide | 2 weeks | Pyrimidine synthesis inhibitor - lowers B and T cell population | Withdraw 2 weeks before surgery; resume after 3 days (controversial) |
| Ciclosporin | 5-18 hours | Inhibits T cell activation by inhibiting calcineurin – cyclophilin ligand | Withdraw 1 week before and 1 week after surgery |
| Azathioprine | 1-3 hours | Purine synthesis inhibition – inhibits cell proliferation | Maintain usual dosage |
| Mycophenolate mofetil | 16-18 hours | Restricts T and B cell proliferation – action upon purine-synthesising enzyme | Withdraw 1 week before surgery; resume 1 to 2 weeks after surgery |

* in special situations (Chronic kidney disease, poorly controlled diabetes mellitus, etc.): methotrexate should be suspended one week before. Adapted from references 12, 34, 39, 40 and 41.

### Table 4 - Biological agents - Half-life, mechanism of action, management during perioperative period and major side effects.

| Drug | Half-life | Mechanism of action | Management | Side effects |
|------|-----------|---------------------|------------|-------------|
| Etanercept | 3.5 – 5.5 days | Anti-TNF | Withdraw 10 days before surgery | Increased risk of infection |
| Adalimumab | 10 – 20 days | B cell inhibitor | Withdraw 30 days before surgery | Increased risk of infection, headache, gastrointestinal disorders |
| Infliximab | 9.5 days | IL-6 receptor antagonist | Withdraw 19 days before surgery | Increased risk of infection, Stevens-Johnson syndrome, hypotension, arrhythmias |
| Certolizumab | 14 days | IL-1 receptor antagonist | Withdraw 28 days before surgery | Increased risk of infection, hepatotoxicity |
| Golimumab | 14 days | IL-1 receptor antagonist | Withdraw 28 days before surgery | Increased risk of infection, hepatotoxicity |
| Abatacept | 12.6 days | T cell inhibitor | Withdraw 25 days before surgery | Increased risk of infection, headache, gastrointestinal disorders |
| Rituximab | 18 – 22 days (effects can last for months) | B cell inhibitor | Withdraw 100 days before surgery | Increased risk of infection, Stevens-Johnson syndrome, hypotension, arrhythmias |
| Tocilizumab | 11 – 13 days | IL-6 receptor antagonist | Withdraw 26 days before surgery | Increased risk of infection, hepatotoxicity |
| Anakinra | 4 – 6 hours | IL-1 receptor antagonist | Withdraw 1 to 2 days before surgery | Increased risk of infection, hepatotoxicity |

Adapted from reference 34.
Biological drugs

Biological agents are newer, high cost drugs with specific mechanisms of action for each molecule - they are antibodies against a target molecule. Within rheumatology, the main agents used are those that antagonize TNF, IL-1, IL-6, CD20 and costimulatory molecules. The mechanism of action, half-life, management during the perioperative period and main side effects of each of the various biologic agents are summarized in Table 4.

For minor procedures, there is no need to interrupt most of these agents, since there is no evidence of increased risk of infection or impaired healing of the surgical site (12). However, for major surgeries, their interruption is recommended for at least twice their half-lives before surgery and may be resumed from 10 to 14 days after surgery (9,39–43), since all of these agents increase the risk of infections. Some drugs, as rituximab, an anti-CD20 monoclonal antibody that depletes populations of B lymphocytes, have a longstanding effect, beginning 2 to 3 weeks after drug introduction and lasting up to 12 months after withdrawal. Severe hypogammaglobinemia is a rare adverse effect of rituximab that could lead to infections. Serum IgG levels may be assessed prior to surgery and patients with low values (IgG < 500 mg/L) may receive intravenous immunoglobulin replacement therapy (44,45).

More studies are necessary to develop guidelines with strong evidence about the safety and management of drugs in the perioperative period in patients with rheumatic diseases. The differentiation of elective procedures and emergency surgeries would also be an important matter for the medical community to reduce infections and complications after surgery.

■ CONCLUSION

Knowing the various drugs used in patients with rheumatic diseases is necessary because their side effects can modify the progression of the postoperative period. Hence, every physician, before suggesting surgical procedures or following the postoperative evolution of a rheumatoid patient, should be capable of managing continuous-use drugs. The most important measures to remember are: a) Aspirin intake for secondary cardiovascular prevention should be maintained during perioperative period for most surgeries; b) NSAIDs should be suspended for hours or even days according to half-life time before surgical procedure; c) Glucocorticoid prescription must be made according to surgical stress; d) Methotrexate, hydroxychloroquine and azathioprine should be maintained during perioperative period; e) biological agents are recommended to be suspended 2 half-lives prior to surgery; f) the administration of such drugs should be restarted based on clinical status and absence of complications (infections and bleeding).

■ ACKNOWLEDGMENTS

This study was supported by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq #301805/2013-0 to RMRP) and Federico Foundation (to RMRP).

■ AUTHOR CONTRIBUTIONS

Franco AS, Iuamoto LR and Pereira RM were responsible for the study design, critical analysis, manuscript drafting and approval of the final version of the manuscript. Franco AS and Iuamoto LR were responsible for the literature review. Franco AS and Pereira RM were responsible for revising the manuscript content. All the authors take responsibility for the integrity of the data analysis.

■ REFERENCES

1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(3):15-25, http://dx.doi.org/10.1002/art.23177.
2. Radner H, Yoshida K, Smolen JS, Solomon DH. Multimorbidity and rheumatic conditions-enhancing the concept of comorbidity. Nat Rev Rheumatol. 2014;10(4):252-6, http://dx.doi.org/10.1038/nrrheum.2013.212.
3. Marsico A, Atzeni F, Piroddi A, Cazzolla M, Stisi S, Sazzi-Puttini P. Costs of pain in rheumatology. Reumatismo. 2014;66(1):103-7, http://dx.doi.org/10.4081/reumatismo.2014.771.
4. Arend WP, Lawry G V. APPROACH TO THE PATIENT WITH RHEUMATIC DISEASE. In: Goldman L, Schater AI, editors. Goldman’s Cecil Medicine. 24th ed. Saunders; 24 edition; 2011. p. 2704.
5. Perioperative Evaluation [Internet]. [cited 2015 May 29]. Available from: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/preventive-medicine/perioperative-evaluation/Default.htm.
6. Bongartz T. Elective orthopedic surgery and perioperative DMARD management: many questions, fewer answers, and some opinions… J Rheumatol. 2007;34(4):653-5.
7. Pess R, Thornhill TS, Ewald FC, Thomas WH, Batte NJ, Sledge CB. Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop Relat Res. 1984;(182):117-26.
8. Schrampa JC, Espehaug B, Hallan G, Engesaeter LB, Furnes O, Havelin LI, et al. Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective, population-based study on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplast Register. Arthritis Care Res. 2010;62(4):473-9, http://dx.doi.org/10.1002/acr.20363.
9. Green L, Jewell T, Lavrenvch C, Samanta A, Shouer. Anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. Rheumatol Int. 2012;32(1):5-13, http://dx.doi.org/10.1007/s00296-011-2040-6.
10. Smitten AL, Chei HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35(3):387-93.
11. Doran ME, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Rheum Dis Clin North Am. 2002;46(3):557-69, http://dx.doi.org/10.1016/S0889-8577(02)00011-4.
12. Arend WP, Lawry G V. APPROACH TO THE PATIENT WITH RHEUMATIC DISEASE. In: Goldman L, Schater AI, editors. Goldman’s Cecil Medicine. 24th ed. Saunders; 24 edition; 2011. p. 2704.
13. Härle P, Straub RH, Fleck M. Elective surgery in rheumatic disease and immunosuppression: to pause or not. Rheumatology. 2009;48(10):1799-800, http://dx.doi.org/10.1093/rheumatology/keq049.
14. Henein CR, Gardner GC, Kadal NJ. Perioperative, Kadal NJ. Perioperative management: many questions, fewer answers, and some opinions… J Rheumatol. 2007;34(4):653-5.
15. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000;40(2):124-32, http://dx.doi.org/10.1174/0091270002200766.
16. Osscarson A, Gupta A, Fredriksen M, Järhult J, Nyström M, Pettersson E, et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth. 2010;104(3):305-12, http://dx.doi.org/10.1093/bja/aeq003.
17. Möllmann H, Nef HM, Hamn CW. Clinical pharmacology: antiplatelet therapy during surgery. Heart. 2010;96(12):986-91, http://dx.doi.org/10.1136/hrt.2008.155655.
18. Gersten NS, Carey MC, Cigarroa JE, Schulman PM. Perioperative aspirin management after POSE-2: some answers, but questions remain. Anesth Analg. 2015;120(3):S70-5, http://dx.doi.org/10.1213/ane.0000000000000889.
19. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):S326-S305, http://dx.doi.org/10.1378/chest.11-2298.
20. Mathiesen O, Wetterles J, Kontinen VK, Pommgardera HC, Nikolajsen L, Rosenberg J, et al. Adverse effects of perioperative paracetamol, NSAIDs, glucocorticoids, gabapentinoinds and their combinations: a topical review. Acta Anaesthesiol Scand. 2014;58(10):1182-98, http://dx.doi.org/10.1111/aas.12380.
21. Connell CS, Parshu RS. Should nonsteroidal anti-inflammatory drugs be stopped before elective surgery? Arch Intern Med. 1991;151(10):1963-6, http://dx.doi.org/10.1001/archinte.151.10.1963-6.
22. Slappendel R, Weber EW, Benzaad B, Dickson R, Bogter ML. Does ibuprofen increase perioperative blood loss during hip arthroplasty? Eur J Anaesthesiol. 2002;19(11):829-31, http://dx.doi.org/10.1016/S0264-7684(02)001345.

23. Tytgat SHAJ, Laman DM, Rijken AM, Klicks R, Voorwinde A, Uitter JM, et al. Emboli rate during and early after carotid endarterectomy after a single perioperative dose of 120 mg acetylsalicylic acid—a prospective double-blind placebo controlled randomised trial. Eur J Vasc Endovasc Surg. 2005 Feb;29(2):156-61, http://dx.doi.org/10.1016/j.ejvs.2004.11.009.

24. Onog W, Shen T, Tan WB, Lomanto D. Is perioperative withdrawal of aspirin necessary in patients undergoing elective inguinal hernia repair? Surg Endosc. 2015;30(12):5428-9, http://dx.doi.org/10.1007/s00464-015-4926-6.

25. Ferraris VA, Swanson E. Aspirin usage and perioperative blood loss in patients undergoing unexpected operations. Surg Gynecol Obstet. 1983;156(4):439-42.

26. Kienapfel H, Koller M, Wüst A, Sprey C, Merte H, Engenhart-Cabillic R, et al. Prevention of heterotopic bone formation after total hip arthroplasty: a prospective randomised study comparing postoperative radiation therapy with indomethacin medication. Arch Orthop Trauma Surg. 1999;119(5-6):296-302, http://dx.doi.org/10.1007/s004020050414.

27. Iorio R, Healy WL. Heterotopic ossification after hip and knee arthroplasty: risk factors, prevention, and treatment. J Am Acad Orthop Surg. 2002;10(6):409-16, http://dx.doi.org/10.5435/00124635-200210000-00005.

28. Axelrod L. Perioperative management of patients treated with glucocorticoids. Endocrinol Metab Clin North Am. 2003;32(2):367-83, http://dx.doi.org/10.1016/S0090-6906(03)00200-4.

29. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954-63, http://dx.doi.org/10.1093/clinids/11.6.954.

30. Wang AS, Armstrong EJ, Armstrong AW. Corticosteroids and wound healing: clinical considerations in the perioperative period. Am J Surg. 2013;206(3):410-7, http://dx.doi.org/10.1016/j.amjsurg.2012.11.018.

31. Salem M, Tainsh RE, Bromberg J, Loriaux DL, Chernow B. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a single preoperative dose of 120 mg acetylsalicylic acid. J Am Acad Orthop Surg. 2005 Feb;13(2):73-8, http://dx.doi.org/10.5435/00124635-200502000-00009.

32. Kehlet H, Binder C. Value of an ACTH test in assessing hypothalamic-pituitary-adrenocortical function in glucocorticoid-treated patients. Br Med J. 1973;2(5859):147-9, http://dx.doi.org/10.1136/bmj.2.5859.147.

33. Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med. 2003;139(3):194-204, http://dx.doi.org/10.7326/0003-4819-139-3-200308050-00009.

34. Gardner C. Management of medications in patients with rheumatic diseases during the perioperative period. In: Mandell B, editor. Perioperative Management of Patients with Rheumatic Disease. 2013.

35. Muniz LF, Pereira RM, Silva TF, Bonda E, Borba EF. Impact of therapy on metabolic syndrome in young adult premenopausal female lupus patients: Beneficial effect of antimalariais. Arthritis Care Res. 2015;67(9):1255-62, http://dx.doi.org/10.1002/acr.22930.

36. Shinjo SK, Boniti E, Wojdyla D, Borba EF, Ramirez LA, Schertharth HR, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 2010;62(3):855-62, http://dx.doi.org/10.1002/art.27300.

37. Ruiz-Irastorza G, Olives N, Ruiz-Arruza I, Martinez-Berriotsoa A, Egurube MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(4):R109, http://dx.doi.org/10.1186/ar2764.

38. Danaa A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus. 2013;22(12):1286-94, http://dx.doi.org/10.1177/0961293613513032.

39. Härle P, Straub RH, Fleck M. Perioperative management of immunosuppression in rheumatic diseases—what to do? Rheumatol Int. 2010;30(8):999-1004, http://dx.doi.org/10.1007/s00296-009-1323-7.

40. Berthold E, Geborek P, Gütte A. Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures. Acta Orthop. 2013;84(5):495-501, http://dx.doi.org/10.3109/17456374.2013.842431.

41. Goodman SM, Paget S. Perioperative drug safety in patients with rheumatoid arthritis. Rheum Dis Clin North Am. 2012;38(4):747-59, http://dx.doi.org/10.1016/j.rdc.2012.08.006.

42. Hirano Y, Kojima T, Kanayama Y, Shioura T, Hayashi M, Kida D, et al. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol. 2010;29(5):495-500, http://dx.doi.org/10.1007/s10067-009-1346-1.

43. den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol. 2007;34(4):689-95.

44. Buch MH, Smolen JS, Berettejide N, Breedveld FC, Burmester G, Dörner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Clin Rheumatol. 2012;31(5):569-80, http://dx.doi.org/10.1007/s10067-011-1815-x.

45. Marco H, Smith RM, Jones RB, Guerry MJ, Catapano F, Burns S, et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord. 2014;15:178, http://dx.doi.org/10.1186/1471-2474-15-178.